• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Opinion.org

#Opinion: opinion matters

  • Sponsored Post
  • About
  • Contact

Wamberg Genomic Survey: 79% of Consumers Would Consider Genetic Testing to Limit Risk of Drug Side Effects

November 13, 2017 By Opinion.org

Pharmacogenomics could help avert adverse drug reactions in about 2 million Americans per year that cause about 100,000 deaths.

Forty percent (40%) of consumers polled think that doctors can reduce the risk of drug side effects in patients through genetic testing, however almost double, 79%, would consider genetic testing, known as pharmacogenomics, to lower their own risk of experiencing drug side effects. Results are based on Wamberg Genomic Consumer Survey, which queried 536 U.S. consumers from 26 to 64 years old. Survey Sampling International (SSI) fielded the survey in October 2017.

The use of prescription drugs increases with age. Often, prescribed medications prove to be ineffective. In the US, serious adverse drug reactions are estimated to occur in about 2 million Americans a year and cause about 100,000 deaths per year, being one of the leading causes of death. Drug side effects also are costly being a significant cause of hospitalization.

The Wamberg Genomic Consumer Survey results are somewhat more favorable than the recent 2017 edition of The Sanofi Canada Healthcare Survey that showed that 67% of members of employee benefit plans report being interested in pharmacogenomic testing.

According to Dr. Phil Smalley, Chief Medical Director of Wamberg Genomic Advisors, “Pharmacogenomic testing allows doctors to prescribe the right drug, at the right dose to the right patient. Most people carry at least one actionable drug-gene variant that, if known, would mean a doctor should use a different drug or altered dose to treat that person. Truly, one size does not fit all.”

He explained that genetically guided prescribing makes drug therapy more effective and helps reduce serious drug side effects. Pharmacogenomic testing is now readily available and affordable.

In the Wamberg survey, respondents were asked:
If you were offered free genetic testing to limit the risk of drug side effects, would you want to get this testing now, whether or not you are currently on medications?

Yes 49%
Considering 30%
Not sure 13%
No 8%
Forty percent (40%) responded this statement was true: “Doctors can reduce the risk of drug side effects by looking at a person’s genetics before taking any medications.”

Other results of the survey revealed the following:

75% responded genetic testing can help people live a longer and better quality of life
33% have had genetic testing. Of those that have had testing, 52% found the results useful
Smalley added, “As more people get their drug-related genes tested, we believe that pharmacogenomics will become widespread. It allows doctors to reduce serious adverse drug reactions and prescribe more effective medications that will improve public health. In addition, it should help lower pharmaceutical costs by more effectively treating patients.”

About the Survey
The Wamberg Genomic Consumer Survey queried 536 U.S. consumers 26-64. The survey was fielded by Survey Sampling International (SSI) in October 2017. Data for the survey was collected via an opt-in panel. The margin of error was 4%.

About Survey Sampling International:
Survey Sampling International (SSI) has been the premier global provider of data solutions and technology for consumer and business-to-business survey research for 40 Years. For more information, go to www.surveysampling.com.

About Wamberg Genomic Advisors:
Wamberg Genomic Advisors’ mission to make genomic testing readily available at prices everyone can afford. Our focus is on delivering genomic products and services to employers and their employees via their trusted benefit brokers, and policyholders of life insurance companies. To learn more visit wamberggenomic.com.

Filed Under: Opinion Tagged With: Genomic Survey, Pharmacogenomics

Footer

Recent Posts

  • Trump Is Right About the AI Race With China, Even After the Coxon Warning
  • How Authoritarian States Captured UN Machinery Under Guterres, and Why the Secretary-General Is Always Chosen Weak
  • Qatar and Turkey Funded the Infrastructure Behind Europe’s Palestine Protests
  • Who’s Going to Tell Trump That Kim Jong Un’s “Respectful” Country Starves Its Own Citizens
  • Ukraine Picked the Right Target in Wildberries, and the Kremlin’s Reaction Proves It
  • Trump, Iran, and the Mars Attacks Problem: Five Months of Cancelled Strikes
  • Ceuta Border Surge Strips Sánchez of His Last Lever and Revives Spain’s Enclave Problem
  • Trip.com’s $765 Million Apology: What the SAMR Penalty Tells Foreign Companies About Doing Business in China
  • Trump’s Section 301 Probe of the EU Tech Fines Is Right, and It Pains Me to Write That
  • Trump’s Saudi Nuclear Deal Trades Nonproliferation for a Photo Op

Media Partners

  • Media Presser
  • k4i.com
  • Policymaker.net
DeepSeek's Huawei Training Bet, Google's €403M Ireland Fine, and Alibaba's New Qwen Chief
September 11 Wire Digest: Antares Lands $161M Space Reactor Award, Tempus Goes After Whole-Genome Scale
Press Release Digest, September 10, 2026: Apple's iPhone Duo, a $1 Billion Space AI Constellation, and EIG's $4 Billion Debt Close
Tech News Digest, September 10, 2026: Apple's $1,999 iPhone Duo, Kepler's $468 Million HBM Bet, and the DOJ's Nvidia-Groq Probe
Amkor Adds $12 Billion in Arizona as AI Capex Shifts to Packaging, Optics and Power
Weekly Network Analytics Summary: August 30 to September 5, 2026
Chinese Rare Earth Suppliers Are Refusing US Orders Weeks Before Xi Visits Washington
Every Supply Chokepoint Has a Shelf Life, Including China's Rare Earth Grip
Inference Prices Are Falling Faster Than Anyone's Budget Assumed
Non-Binding Agreements Now Govern More Than Treaties Do
Borsa Istanbul Fund Scandal: Turkey's Regulator Is Prosecuting the Collapse Its Own Rule Set Off
Fed Hikes Rates for the First Time Since 2023 and the 10-Year Treasury Yield Falls Back Below 5%
Chip Stocks Sell Off on Amodei's Pacing Call While 2026 Capex Forecasts Keep Rising
Saudi Arabia Loses Both Export Routes as the Houthis Reach Bab el-Mandeb
Micron (MU) Slips as Intel-Backed Kepler Computing Takes Aim at Memory With 2,000 Wafers to Its Name
Palantir (PLTR) Gave Back Half of a 9.1% Rally While Snowflake Kept 21%
DFEN Fell 33% in a Month While Its Index Fell Only 11%
Kioxia and Sandisk's $31 Billion NAND Plan Produces No New Bits Until Fiscal 2029
Why Marvell and Memory Stocks Are Down After Nvidia Guided FY28 Growth to 70%
Iran-Linked Hackers Shut Down a UK Power Plant for Four Days: What the Four Days Actually Signal
Trump Declines Saudi Request for Strikes on the Houthis as Bab el-Mandeb Falls
Spain Is Changing — And Pedro Sánchez Should Be Held Accountable
Czech Politics Before the October 2026 Elections: Babiš, President Pavel, and the Ammunition Initiative
Disney's Billion-Dollar OpenAI Deal Raises the Question of Who Gets Locked Out
The New York Times Case Against OpenAI Forced Disclosure of 20 Million ChatGPT Conversations
Iran's Draft Hormuz Transit Plan Bans US and Israeli Ships, Sending Brent Back Above $82
Trump's 20% Hormuz Toll Is Fifteen Times the Iranian Fee He Went to War to Stop
Trump's Real Target With Erdogan Is the Hormuz Bypass, Not the F-35
Mamdani's Slate Is Capturing Congress Through Primaries Almost No One Votes In
Starmer Falls, Burnham Rises, and Britain Changes Prime Minister Without an Election

Media Partners

  • Press Club US
  • 3V.org
  • ZGM.org
Why Social Unrest Has Become a Standing Condition in Europe and the United States
UN Secretary-General Race: Rodrigues Birkett Takes the Lead While Grossi Collects Discourage Votes
BuzzFeed and GB News Cut a Third of Staff Each as 2026 Job Losses Pile Up
Eight Pulitzer Winners and Finalists Used AI in Their 2026 Work
Hormuz Talks Stall, Samsung Stacks Memory on the GPU, Taiwan Slows Its Own Networks: August 10 Briefing
Trump Administration Clears Saudi Nuclear Deal Without Enrichment Safeguards
Lindsey Graham, South Carolina Senator and Foreign Policy Hawk, Dies at 71
The Case Against ICC Jurisdiction Over American Citizens
Why Trump Is Going All In to Please Erdogan
An Open Letter to Government: Leave AI Alone
Press Release Digest: Rubrik Puts Claude Mythos 5 on Code Security, Factory Hits $5 Billion, TeRAM Takes On the AI Memory Wall
Wonderful's $5B Series C: 50x Forward ARR on $154,000 of Revenue Per Employee
Nvidia (NVDA) Buys Hugging Face for $12.9B, Under the $13B Floor Hugging Face Floated Three Days Earlier
Apple's Chinese Memory Push Is a Precedent Problem for $MU and $SNDK, Not a Volume Problem
NYC Sidewalk Sheds and Local Law 11: Why the Shed Is Cheaper Than the Repair
Enigma Raises $70M for Human-Robot Interaction as Multiverse Raises $570M to Shrink Models
Kimi K3 Weights Released as Washington Debates Banning Chinese AI Models
Meta's Hyperion Data Center in Louisiana Was Negotiated With Tax Breaks and Little Public Input
Robots.txt vs Noindex: Why Blocking Crawlers Does Not Remove Pages From Search
Infinity.inc Raises $15 Million to Build AI Inference Software for Any Chip
Mid-September Across the Network: Chokepoints, Memory Prices, and the Crawler Block Landing September 15
Scripps Cuts 268 Jobs and Rebuilds Local TV News Around Automation
YouTube's Creator Partnerships API Turns Influencer Deals Into Programmatic Media Buys
Singapore's GDP Upgrade and CoreWeave's $104 Billion Backlog: The AI Boom Has Reached the Lagging Indicators
SanDisk (SNDK) $4,000 Price Target: The Case Rests on the Multiple, Not the Earnings
ADBE Two-Month High on Topaz Labs FTC Clearance: A Sub-$1 Billion Tuck-In That Buys Gross Margin, Not Features
A Ban on Chinese Open Models Would Fail, and Kimi K3 Just Proved It
AI Wrote the Pickup Line and Google Indexed the Conversation
Together AI Raises $800M Series C at $8.3B Valuation to Scale Open Source Inference
Technology, Finance, and Smart City Events: Selected Global Calendar, 2026

Copyright © 2026 Opinion.org

Media Partners: Market Analysis · Market Research · Referently · Photography · Hormuz · Taiwan Strait · Policy Maker · Publishing House

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT